Head-to-head · Cost-Efficiency Index
Invigor Medical vs Aquivia Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalAquivia Health
Cost-first shoppers who want clinician-reviewed compounded GLP-1 with optional branded upgrade.
Visit Aquivia HealthThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 61. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. Aquivia Health still earns a C — Cost-first shoppers who want clinician-reviewed compounded GLP-1 with optional branded upgrade.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | Aquivia Health |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 61/100 |
| Semaglutide / mo | $199/mo | $149/mo |
| Tirzepatide / mo | $339/mo | $179/mo |
| Semaglutide / yr (modeled) | $2,388 | $1,788 |
| Tirzepatide / yr (modeled) | $4,068 | $2,148 |
| Coverage | Not disclosed | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #8 | #219 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
Aquivia Health
61/100Where the value is
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
The tradeoffs
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.